Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis

Journal of Experimental Medicine

Volumn 195, Issue 12, 2002, Pages 1575-1584

  Li, Yiwen ^a   Wang, Mei Nai ^a   Li, Hongli ^a   King, Karen D ^a   Bassi, Rajiv ^a   Sun, Haijun ^a   Santiago, Angel ^a   Hooper, Andrea T ^a   Bohlen, Peter ^a   Hicklin, Daniel J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Angiogenesis; Antibody; Cancer vaccine; Cytotoxic T lymphocytes; Tumor antigen

Indexed keywords

NEUTRALIZING ANTIBODY; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ACTIVE IMMUNIZATION; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENDOTHELIUM CELL; FEMALE; IMMUNOLOGICAL TOLERANCE; LEWIS CARCINOMA; MELANOMA; METASTASIS; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SURVIVAL; TUMOR;

ANIMALS; CARCINOMA, LEWIS LUNG; FEMALE; IMMUNOTHERAPY; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 0037124333     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20020072     Document Type: Article

References (40)

1. Human tumor antigens recognized by T lymphocytes
2. Cancer antigen: Immune recognition of self and altered self
3. Human tumor antigens for cancer vaccine development
4. Tumor immunology
5. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance
6. Molecular mechanisms of developmental and tumor angiogenesis
7. What is the evidence that tumors are angiogenesis dependent?
8. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
9. Failure of blood-island formation and vasculogenesis in Flk-1 deficient mice
10. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
11. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
12. Anti-VEGF receptor (Flk-1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors
13. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library
14. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
15. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: Concentration in tumor blood vessels
16. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer
17. Dendritic cells as adjuvants for immune-mediated resistance to tumors
18. Progressive growth in immunodeficient mice and host cell recruitment by mouse endothelial cells transformed by polyoma middle-sized T antigen: Implications for the pathogenesis of opportunistic vascular tumors
19. Down-regulation of platelet endothelial cell adhesion molecule-1 results in thrombospondin-1 expression and concerted regulation of endothelial cell phenotype
20. Heparin modulates the interaction of VEGF165 with soluble and cell associated flk-1 receptors
21. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor
22. The role of IL-13 in the generation of dendritic cells in vitro
23. Protective immunity induced by B7/CD28-costimulated gamma delta T cells to the EL-4 lymphoma in allogenic athymic mice
24. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis
25. A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate-encapsulated tumor cells
26. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine
27. Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development
28. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2
29. Cell typespecific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis
30. Expression and function of angiopoietin-1 in breast cancer
31. Role of alpha v integrins during angiogenesis
32. Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis
33. The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors-lessons from normal and immunodeficient mice
34. Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth
35. Expression of vascular endothelial growth factor receptors in the human endometrium: Modulation during the menstrual cycle
36. Expression of vascular endothelial growth factor and its receptors in the human corpus luteum during the menstrual cycle and in early pregnancy
37. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies
38. Coordinated induction of VEGF receptors in mesenchymal cell types during rat hepatic wound healing
39. Bacterial wall products induce downregulation of vascular endothelial growth factor receptors on endothelial cells via a CD14-dependent mechanism: Implications for surgical wound healing
40. The angiogenesis inhibitor vasostatin does not impair wound healing at tumor-inhibiting doses